ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2026
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus (T2DM) and obesity represent two major global health challenges. Amylin-based agonists offer a promising perspective. Three frontrunner agents of this class are increasingly being investigated: zenagamtide, eloralintide and cagrilintide-semaglutide (CagriSema).
methodsA search in PubMed/MEDLINE, Scopus and Google Scholar was conducted with the use of appropriate keywords until June 2026 for this narrative review.
resultsZenagamtide (formerly known as amycretin), a unimolecular long-lasting amylin and glucagon-like peptide-1 receptor (GLP-1R) co-agonist, achieved weight loss up to 13.1% (phase 1 study, 85 days) in obesity trials as an oral formulation and up to 24.3% (phase 1b/2a study, 36 weeks) as a subcutaneous formulation. Moreover, eloralintide, a long-acting mostly amylin type 1 receptor (AMY1R) agonist, achieved weight loss up to 20.1% (phase 2 study, 48 weeks), and CagriSema resulted in weight loss up to 22.7% (phase 3a study, 68 weeks). All these agents reduced body mass index (BMI) and waist circumference (WC). In T2DM, CagriSema reduced glycated haemoglobin (HbA
conclusionsThese agents hold therapeutic potential in the management of both T2DM and obesity, as shown by preliminary clinical trial outcomes. Further trials are now needed to validate them in clinical practice.
Indexed as
Identifiers
42803913What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.